Showing results (301-310 of 1,750) with videos related to
Sort By:
Pageof 175
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 26, 2006
Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditionsJudy C Peng, Claire Hyde, Saparna Pai, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 26, 2006
Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectorsMichal Lotem, Yangbing Zhao, John Riley, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 26, 2007
4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family membersHidde M Kroon, Qiao Li, Seagal Teitz-Tennenbaum, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 26, 2007
Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapyDaniel J Powell, Christiaan R de Vries, Tamika Allen, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 26, 2007
Environmental enrichment augments the efficacy of idiotype vaccination for B-cell lymphomaNoa Benaroya-Milshtein, Alan Apter, Isaac Yaniv, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 26, 2007
Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptideSybren L Meijer, Annemieke Dols, Shawn M Jensen, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanomaFranz O Smith, Jacob A Klapper, John R Wunderlich, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
CD167 acts as a novel costimulatory receptor in T-cell activationNana Dang, Jinsong Hu, Xinping Liu, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC)Martin Klehr, Ulrike Koehl, Martina Mühlenhoff, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 29, 2010
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) studySebastiano Buti, Silvia Lazzarelli, Matteo Dalla Chiesa, et al.Pageof 175